🇺🇸 Cabozantinib group in United States

FDA authorised Cabozantinib group on 25 April 2016

Marketing authorisations

FDA — authorised 25 April 2016

  • Application: NDA208692
  • Marketing authorisation holder: EXELIXIS INC
  • Local brand name: CABOMETYX
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA

  • Status: approved

Cabozantinib group in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Cabozantinib group approved in United States?

Yes. FDA authorised it on 25 April 2016; FDA has authorised it.

Who is the marketing authorisation holder for Cabozantinib group in United States?

EXELIXIS INC holds the US marketing authorisation.